HC Wainwright & Co. Maintains Buy on Rallybio, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a Buy rating on Rallybio (NASDAQ:RLYB) but lowers the price target from $17 to $12.

February 07, 2024 | 11:26 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Rallybio's price target was lowered from $17 to $12 by HC Wainwright & Co., although the Buy rating was maintained.
The reduction in price target could have a mixed impact on Rallybio's stock. On one hand, the lowered price target might suggest a tempered outlook, potentially leading to short-term negative sentiment among investors. On the other hand, maintaining a Buy rating indicates a positive view on the company's fundamentals and potential for growth, which could mitigate negative reactions. The net impact is considered neutral due to these counterbalancing factors.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100